The State Key Laboratory of Antiviral Drugs (abbreviated as the SKL of Antiviral Drugs) was approved for construction by the Ministry of Science and Technology (MOST) in March 2023. As a newly established national key laboratory, it was jointly applied for by Henan Normal University, Zhengzhou University, and Henan University as the supporting institutions.

The Laboratory consistently adheres to the Four Orientations and implements the national Healthy China strategy. Taking major scientific and technological challenges in the R&D of innovative antiviral drugs as its main focus, the Laboratory specializes in the research and development of nucleoside antiviral drugs, forming distinctive research directions with significant advantages. It is dedicated to scientific research, technology development, talent cultivation, and academic exchanges. By proposing original theories, breaking through key and core technologies, and developing nucleoside antiviral drugs with fully independent intellectual property rights, the Laboratory is committed to building a national strategic scientific and technological force in antiviral drug R&D.